Nine Midsized Pharmaceutical Firms Join Voluntary Medicaid Pricing Initiative

drugmakers have now signed voluntary pricing agreements with the Trump administration in roughly a year, according to Bloomberg Law News, with nine midsized manufacturers joining on Monday in a deal designed to bring US Medicaid drug prices in line with cheaper rates charged overseas. The agreements raise a sharp policy question: by negotiating directly with the White House, are these companies effectively carving out a shield from more sweeping, mandatory Medicare pricing pilots now under review?

A growing voluntary cohort

The newest signatories include BeOne Medicines, BridgeBio Pharma, Teva Pharmaceuticals, Sun Pharmaceutical Industries, and Incyte, per Bloomberg Law News. Each has pledged undisclosed discounts on certain medicines so that what state Medicaid programs pay reflects international benchmarks rather than US list prices. The cohort now spans 26 manufacturers over the past year, a meaningful expansion that suggests the voluntary track is gaining traction across the industry rather than remaining a one-off arrangement.

That growth has a practical dimension worth weighing. Lower state-level prices can translate into steadier formulary access for Medicaid patients, particularly for branded specialty therapies where list price has historically constrained uptake. It is a clinical outcome rather than a symbolic one.

The exemption question

Here is the tension. The Centers for Medicare & Medicaid Services is preparing two mandatory pilot programs that would test alternative rebate calculations under Medicare Part B and Part D, pegged to international pricing metrics. Unlike the voluntary deals, participation would not be optional. Bloomberg Law News reports that several of the companies signing Monday have indicated they expect to be exempt from those pilots, and CMS has not confirmed whether existing arrangements would grant such exclusions.

The result is a narrowing pool of manufacturers potentially subject to mandatory pricing pressure, concentrated among smaller firms without a White House agreement. A Harvard Medical School assistant professor, Thomas Hwang, told Bloomberg Law News that the remaining "slice" of the industry available for mandatory pilots keeps shrinking, while Kristi Martin, a former CMS chief of staff now at Camber Collective, framed the math bluntly: smaller companies may be the only ones left to bear the weight of a mandatory model.

Drugmakers counter that pegging US prices to overseas rates imports other countries' valuation decisions and could chill investment in new therapies, an argument made by Christopher Schott, a partner at Latham & Watkins advising manufacturers. CMS, for its part, plans to use its Section 1115A authority to launch the demos once final rules are cleared by the White House.

What to track next

Three signals will determine whether this approach actually moves US drug costs lower. First, the final scope of the Part B and Part D pilots after review, specifically whether the voluntary cohort effectively shrinks the mandate to a sliver of the market. Second, the actual discount levels states negotiate under these agreements, since the published figures remain undisclosed. Third, the share of new branded launches whose list prices shift in response to international benchmarks, which would indicate the policy is reaching beyond Medicaid into the broader market.

For now, the administration's voluntary track is yielding measurable participation. Whether it yields measurable savings will depend on the numbers it has not yet released.